Ophthalmology

Experts in the field weigh in on and give opinions on the question "What do you wish patients knew about eye health."

Experts in the field weigh in on and give opinions on the question "What do you wish patients knew about eye health."

Experts in the field weigh in on and give opinions on the question "What do you wish patients knew about eye health."

The company announced its previously announced agreement to divest its late-stage ophthalmic assets to Laboratoires Théa S.A.S. has been terminated.

We spoke with researchers and industry professionals at the 2023 ASRS meeting in Seattle, Washington. We asked them, "What do you wish patients knew about eye health?" Here's what Michael Ip, MD, Shawn Kavoussi, MD, and Megan Baldwin, PhD, had to say!

Ocuphire Pharma and Viatris developed the drug together for the reversal of pharmacologically-induced mydriasis (RM) produced by adrenergic agonist or parasympatholytic agents.

We asked, "What do you wish patients knew about eye health?" Here's what Durga Borkar, MD, MMCi, Aaron Lee, MD, and Carl Dazig, MD, had to say!

Kiora CEO Brian Strem, PhD, offers an update on the development of KIO-301, a molecule that selectively targets retinal ganglion cells, giving them the ability to sense light.

The research will focus on the compound's impact on biomolecular condensates, which are implicated as a key driver of pathology in neurodegeneration and diseases impacting high metabolic organs. Because the retina is one of the highest energy consuming systems in the human body, deficits in energy supply can be catastrophic.

According to the companies, the partnership will roll out a proprietary system that has earned FDA breakthrough designation, one of the few ophthalmic devices to achieve this status in almost a decade.

Researchers from the University of Barcelona are looking to unlock the function of genes in order to design therapies to treat patients diagnosed with retinitis pigmentosa.

The theme calls on employers, insurers, and policy makers to consider how they can contribute to improved access to vision and eye health care.

With a robust pipeline, new hope for Stargardt disease and retinitis pigmentosa may be on the horizon.

The AI retinal scanning model will be free to use for all institutions.

According to the company, the clinical study update suggests continued positive trends in best-corrected visual acuity and multi-luminance mobility testing as well as positive trends in low-luminance visual acuity among treated eyes.

A panel of esteemed retina specialists recently delved into innovative therapies for neovascular age-related macular degeneration and diabetic macular edema, focusing on personalized treatment, telemedicine, and the ongoing quest for advancements.

The Ophthalmic World Leaders (OWL) Leadership Summit, scheduled for September 21 and 22, 2023, in Austin, Texas, will feature a lineup of prominent speakers and engaging discussions on a wide range of leadership topics and industry insights.

Alex Gorsky currently sits on the boards of Apple, IBM, JPMorgan Chase, and the Travis Manion Foundation, as well as the Wharton School of the University of Pennsylvania Board of Advisors.

Walgreens Boots Allianc Inc. and CVS Health are among the companies the FDA sent letters to for violating federal law.

The company is expanding its patent portfolio to 10 granted patents and 32 pending patent applications.

According to the company, OPGx-LCA5 is designed to address vision loss due to Leber congenital amaurosis associated with mutations in the LCA5 gene, which causes one of the most severe early-onset retinal dystrophies.

According to the companies, the collaboration has the potential to benefit patients who have suffered from specific, chronic ocular diseases.

Ocular Therapeutic, Rezolute, and Opthea will all present at the H.C. Wainwright 25th Annual Global Investment Conference being held in New York City in September.

The beauty brand announces Ashley Brissette, MD, MSc, FRCSC, will be the brand's first guiding ophthalmologist.

DMEI is 1 of only 17 centers in the US certified to provide this specialized treatment. Previously, patients in the region who qualified for LUXTURNA would have had to travel to other states to receive treatment.

According to the company, NFS-05, utilizes a gene therapy approach that delivers an AAV vector containing the OPA1 gene into the vitreous cavity.

The 6-month-old boy’s dark brown eyes turned deep blue after he was treated for COVID with favipiravir.

EyeSouth Partners has partnered with Retina and Vitreous of Texas, a retina-only practice in Houston, Texas. The company’s current network encompasses 38 practices and over 300 doctors who deliver medical and surgical eye care services across more than 180 locations.

According to the company, the tool provides free access to training and mentors for eye care professionals in areas with the greatest need, and the new Cybersight mobile app expands access for eye care professionals through offline functionality.

Prevent Blindness declares September as Sports Eye Safety Month to educate the public on the risk of significant eye injuries and the need for the proper sports eye protection.